(Q46787767)

25 December 2017

title

Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice (English)

1 reference

25 December 2017

0 references

2

M Jutel

1 reference

25 December 2017

F Bonifazi

1

1 reference

25 December 2017

B M Biló

3

1 reference

25 December 2017

J Birnbaum

4

1 reference

25 December 2017

U Muller

5

1 reference

25 December 2017

EAACI Interest Group on Insect Venom Hypersensitivity

6

1 reference

25 December 2017

publication date

1 December 2005

1 reference

25 December 2017

published in

Allergy

1 reference

25 December 2017

volume

60

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

page(s)

1459-1470

1 reference

25 December 2017

Clinical guidelines: developing guidelines

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Epinephrine absorption in adults: intramuscular versus subcutaneous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Lessons for management of anaphylaxis from a study of fatal reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Regulatory T cells in autoimmmunity*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

CD4(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Diagnosis of Hymenoptera venom allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

ACE inhibitors and anaphylactoid reactions during venom immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Natural history of large local reactions from stinging insects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Venom immunotherapy in the Hymenoptera-allergic pregnant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Allergy to bumblebee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Successful treatment of occupational allergy to bumblebee venom after failure with honeybee venom extract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Double sensitization to honeybee and wasp venom: immunotherapy with one or with both venoms? Value of FEIA inhibition for the identification of the cross-reacting ige antibodies in double-sensitized patients to honeybee and wasp venom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Safety of venom immunotherapy administered by a cluster schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Rush venom immunotherapy program for honeybee sting sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Combination of passive and active immunization in honeybee venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Combined active and passive immunotherapy in honeybee-sting allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Regimens of Hymenoptera venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Early effect of ultrarush venom immunotherapy on the IgG antibody response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Comparison of Vespula germanica venoms obtained from different sources.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Rapid venom immunotherapy update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Recombinant Hymenoptera venom allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Prolonged maintenance interval in hymenoptera venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Assessment of prolonged venom immunotherapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Prospective observations on stopping prolonged venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Clinical and immunologic follow-up of patients who stop venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Discontinuing venom immunotherapy: outcome after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Recent developments and future strategies for immunotherapy of insect venom allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2005.00960.X

10.1111/J.1398-9995.2005.00960.X

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017